Searched for
ANTIBIOTICS PRICE
For investors with ability – and patience to wait 3 years, not 3 months: 6 large-cap stocks with upside potential of up to 33%The interesting point about the large-cap space today is not that prices have collapsed. In most cases, they have not. The more important c...- Drugmakers yet to see gains from government's minimum import price policyGovernment's Minimum Import Price (MIP) initiative to boost domestic drug makers faces a slow start. Despite setting price thresholds for k...
- Scanning cancer, up close & personal: A revolution is underway in cancer diagnosisA gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Sinc...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 26%Just look at developments in the past 48 hours. The war between Iran and Israel resumed, but within hours Tehran said it had halted all off...
- CG Power's growth momentum strong, but valuation comfort missing: Sandip SabharwalCG Power expands its switchgear production, signaling strong demand in the power equipment sector. However, market expert Sandip Sabharwal ...
- FirstClub raises $55 million from Peak XV, Sofina; valuation doubles to $255 millionQuality-focused grocery delivery startup FirstClub has secured $55 million in a Series B funding round led by Peak XV Partners and Sofina, ...
- Metals rally largely priced in, limited upside seen after strong cyclical run: Sandip SabharwalMarket expert Sandip Sabharwal advises caution, seeing stock-specific chances but limited broad market conviction. He notes Wockhardt's app...
- Wockhardt shares pause massive 36% rally in 5 sessions; slip 7%. What’s behind the selloff?Wockhardt shares dropped after a recent surge, as investors took profits. This followed the US FDA approval of ZAYNICH, an antibiotic for u...
- Zaynich's blockbuster potential lifts Wockhardt's long-term outlookWockhardt's novel antibiotic, Zaynich, has received USFDA approval after a 12-year effort, sparking hopes for a turnaround after years of n...
- If you have the patience, you can achieve innovation milestones, says Wockhardt chairman Habil KhorakiwalaWockhardt Hospitals is set to launch its antibiotic Zaynich in the US. Zahabiya Khorakiwala will lead US operations. The drug is expected t...
- Good news for diabetes & BP patients: Govt cuts prices of these 30 medicines, relief may reach pharmacies soonThe National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices for 30 essential drug formulations, including those for diabet...
- Infosys, Tech Mahindra, TCS and other IT stocks jump up to 5%. What’s driving the rally?Indian IT stocks rose sharply on Monday, lifting the Nifty IT index nearly 3%, as investors reassessed AI-related fears, attracted by attra...
- More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...
- Wockhardt secures US FDA approval for antibiotic ZaynichWockhardt's novel antibiotic, Zaynich (cefepime and zidebactam), has received US FDA approval for complicated urinary tract infections. Thi...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 22%As the market grappled with confusion over the Strait of Hormuz, there was more trouble for the bulls. After a few days of respite, another...
- Wockhardt shares jump 8%, extend rally after CDSCO nod for Zaynich antibioticWockhardt shares surged after the company received CDSCO approval for its breakthrough antibiotic Zaynich in India. Strong Phase 3 trial re...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...
- Now smaller firms developing antibiotics but will society, politicians accept high prices?As a woman dies in the US from a superbug infection likely caught in India, four domestic companies are taking up the cudgels in the area o...
- Standing guard: NPPA asked to monitor prices of antibioticsThe department of pharmaceuticals, or DoP, has asked the country’s drug price regulator to be on guard against a possible spike in antibiot...
Load More
